Knowledge on hydroxychloroquine prescription and attitude toward its use in COVID-19 – A survey-based study among doctors
| Autor: | N. A. Uvais, S. Eliyas, Anuradha Bishnoi, N. Bishurul Hafi, T. P. Afra, E. Sukesh, T. Razmi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
knowledge hydroxychloroquine physician Coronavirus disease 2019 (COVID-19) business.industry Hydroxychloroquine Target population Guideline Diseases of the musculoskeletal system Patient care Clinical trial Knowledge score Rheumatology covid-19 RC925-935 Family medicine attitude medicine survey Medical prescription business medicine.drug doctors |
| Zdroj: | Indian Journal of Rheumatology, Vol 16, Iss 2, Pp 194-199 (2021) |
| ISSN: | 0973-3701 0973-3698 |
| Popis: | Background: The use of hydroxychloroquine (HCQ) in COVID-19 had garnered enormous media attention. There were conflicting reports as well as unscientific opinion pieces in the scientific literature also. This study was planned to assess the knowledge, attitude, and practice of health-care professionals regarding HCQ. Methods: An online survey was created with 8 knowledge-based questions (n = 2 fact-based [each scoring 1], n = 6 guideline-based [each scoring 2]), and 6 attitude-based questions, and distribution among a target population of doctors was done using Google™ forms. Results: Of 115 respondents, the majority considered HCQ a safe drug (86.1%) and were in favor of its usage in COVID-19 trials (81.7%) or health-care/contact prophylaxis (60.9%) but against its use as a mass prophylactic agent (80.9%). Contrary to the published guidelines/recommendations, 80% and 55.7% of respondents opined for routine cardiac and glucose-6-phosphate dehydrogenase evaluations before prescribing HCQ. Those who were dealing with COVID-19 patients directly (n = 41) had significantly lower knowledge score compared to the others (6.37 vs. 7.72, P = 0.007). They had significantly lesser awareness for the baseline tests recommended (97.6% vs. 77.0%, P = 0.003). A significantly higher number of these physicians opposed the use of HCQ in clinical trials (26.82% vs. 8.1%, P = 0.027) and health-care/contact prophylaxis (41.5% vs. 16.2%, P = 0.008). Conclusion: Sparse and speedily gathered information on HCQ can influence the practicing doctors, especially those involved directly in COVID-19 patient care, but less familiar with the prescription of this time-tested drug. Possibly, this has a bearing on the counseling of the patients requiring HCQ for non-COVID-19 indications and formulation of new guidelines. © 2021 Wolters Kluwer Medknow Publications. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|